Celgene Becomes a Bargain Once Again [View article]
and this
WASHINGTON (Dow Jones)--The Food and Drug Administration said Thursday that Celgene Corp.'s (CELG) blood-cancer drug Revlimid may cause a rare but serious skin reaction in some patients.
The agency released a post-marketing review of Revlimid as part of a quarterly drug-safety newsletter that was posted to the agency's Web site. The review discussed 14 reports of serious skin reactions possibly linked to the drug.
Earlier this month, Revlimid appeared on a list of about 20 drugs that the FDA said it was investigating after receiving reports of various post-marketing safety issues but details weren't released.
The FDA said doctors need to be aware of the possibility that Revlimid could cause serious skin reactions and said the drug should be discontinued if a skin rash appears. The skin-reaction possibility is not currently contained in Revlimid's label, which partly serves as tool to warn doctors about drug risks, the FDA said.
Brian Gill, a spokesman for the Summit, N.J., company, said it was likely that the label for Revlimid would be updated to include reports of the skin reactions. He said about 60,000 patients have been treated with Revlimid.
Revlimid was approved in December 2005 to treat a bone-marrow disorder known as myelodysplastic syndromes and later approved for multiple myeloma, a type of blood cancer.
Since approval, the FDA said it had received 14 reports of serious skin reactions, known as Stevens-Johnson syndrome or toxic epidermal necrolysis, through January 2008. The agency said it received three reports of deaths in patients with the skin conditions, although in one case the cause of death was listed as progression of a type of blood cancer.
The skin conditions are two related skin disorders characterized by blisters that typically result from drug exposure. The agency said eight of the patients had reported either taking or previously being on other drugs that could have also caused the skin reactions. However, the FDA said in at least two cases it appeared that Revlimid played a role in the development of skin reaction.
Revlimid already carries the FDA's toughest black-box drug warning discussing the possibility of birth defects and other serious problems, such as blood clots, and is sold under a restricted distribution system.
Is There a Bounce Opportunity in the Energy Sector? [View article]
no. Crack spread dropped 20% and crude is in backwardation. Refiner utilization is in the mid 70s what will happen to refiners when it gets to the mid 80s?
The USO might not look strong but APC, DVN, XTO and other solid E&Ps have built a nice base and strong gains from the time the $bpener gaves us the last buy signal.
Railway Stocks Haul Transportation ETF to Solid Returns [View article]
What were your thoughts behind the huge put buying in the rails the past several weeks. Is this hedging or a sector rotation. My fav rail over the years has been GWR.
Valero, Tesoro: Margin of Security in Refinery Assets [View article]
<I think that the long term trend in oil is up, for the usual reasons: finite supply, increasing demand from China and India, and geopolitical tensions. VLO and TSO both provide a valuable service and should be able to participate in the trend.>
If crude's trend is up then the crack spread margins will continue to be pressured, less money less profit for refiners.
"opening long positions here would mesh well with a trend we’ve seen consistently this week of traders extending defensive positions further into late 2008/early 2009"
Sort by:
Latest | Highest rated15 Long Ideas for Buying on Strength [View article]
Tuesday Options Update: XLF, BAC, C, MS, EXPE, RHT, JCI [View article]
thanks
Celgene Becomes a Bargain Once Again [View article]
WASHINGTON (Dow Jones)--The Food and Drug Administration said Thursday that Celgene Corp.'s (CELG) blood-cancer drug Revlimid may cause a rare but serious skin reaction in some patients.
The agency released a post-marketing review of Revlimid as part of a quarterly drug-safety newsletter that was posted to the agency's Web site. The review discussed 14 reports of serious skin reactions possibly linked to the drug.
Earlier this month, Revlimid appeared on a list of about 20 drugs that the FDA said it was investigating after receiving reports of various post-marketing safety issues but details weren't released.
The FDA said doctors need to be aware of the possibility that Revlimid could cause serious skin reactions and said the drug should be discontinued if a skin rash appears. The skin-reaction possibility is not currently contained in Revlimid's label, which partly serves as tool to warn doctors about drug risks, the FDA said.
Brian Gill, a spokesman for the Summit, N.J., company, said it was likely that the label for Revlimid would be updated to include reports of the skin reactions. He said about 60,000 patients have been treated with Revlimid.
Revlimid was approved in December 2005 to treat a bone-marrow disorder known as myelodysplastic syndromes and later approved for multiple myeloma, a type of blood cancer.
Since approval, the FDA said it had received 14 reports of serious skin reactions, known as Stevens-Johnson syndrome or toxic epidermal necrolysis, through January 2008. The agency said it received three reports of deaths in patients with the skin conditions, although in one case the cause of death was listed as progression of a type of blood cancer.
The skin conditions are two related skin disorders characterized by blisters that typically result from drug exposure. The agency said eight of the patients had reported either taking or previously being on other drugs that could have also caused the skin reactions. However, the FDA said in at least two cases it appeared that Revlimid played a role in the development of skin reaction.
Revlimid already carries the FDA's toughest black-box drug warning discussing the possibility of birth defects and other serious problems, such as blood clots, and is sold under a restricted distribution system.
Is There a Bounce Opportunity in the Energy Sector? [View article]
Is There a Bounce Opportunity in the Energy Sector? [View article]
Options Trader: Friday Outlook [View article]
Not playing the refiners? Some monster moves over the past several trading days. Long FTO, VLO, TSO stock and calls.
No To Refiners - Cramer's Lightning Round (9/10/08) [View article]
Options Trader: Thursday Outlook [View article]
Tuesday Options Update: UNG, WYE, XLF, GE, AAPL, MRVL, FNM, MCRS, CLNE, CAKE, [View article]
Fast money was pimping the UNG last night. I'd rather trade the e&Ps APC, PXD, XTO among others.
Options Trader: Tuesday Outlook [View article]
Wednesday Options Update: MER, BAC, FNM, AMGN, AMLN, LLY, MEA, GE [View article]
thanks
Railway Stocks Haul Transportation ETF to Solid Returns [View article]
Valero, Tesoro: Margin of Security in Refinery Assets [View article]
If crude's trend is up then the crack spread margins will continue to be pressured, less money less profit for refiners.
Thursday Options Outlook: WPI, ADSK, DNA, NITE, LEN, CTRP, FRX, IDCC [View article]
"opening long positions here would mesh well with a trend we’ve seen consistently this week of traders extending defensive positions further into late 2008/early 2009"
Big Oil Looks to Cash in on Crude Oil Prices [View article]
Inventory numbers don't bear this out. Greater gas and distil inventories with demand destruction China and US spells lower margins.